CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Patient Input and Clinical Experts: Luxturna

Published on: March 25, 2020
Result type: News

CADTH has received the following notice(s) of pending drug submission(s).

Brand name Luxturna
Generic name voretigene neparvovec
Manufacturer Novartis Pharmaceuticals Canada Inc.
Indication(s) Vision loss, inherited retinal dystrophy
Project Number SG0643-000
Call for patient input 2020-03-25
Patient input deadline 2020-05-14
Submit patient input Submit
Register as Clinical Expert Register